Webinar:

Using Computational and Molecular Modeling Techniques to Address Low Solubility and Speed Your Molecule Through Development

Sponsored by: Patheon

Focused on:

  • Small Molecule Drugs
  • Low Soluble Molecules

Date: 30 January

261

Time: 3PM UK Time/10AM New York

Using Computational and Molecular Modeling Techniques to Address Low Solubility and Speed Your Molecule Through Development

Industry estimates suggest that as many as 60-90% of small molecule drugs in development have low solubility, which can lead to extensive trial-and-error experimentation to find the right approach to achieve clinical success. In some cases, not addressing solubility concerns soon enough in development can cause delays or costly clinical failures. Fortunately, addressing solubility does not have to be a time-consuming, expensive and risky endeavor.

Join our webinar and hear a panel of Patheon experts review the challenges with developing low-soluble molecules and the benefits of leveraging computational and molecular modeling tools like Patheon Quadrant 2®, including:
• accelerated selection of lead formulations and candidate drug-excipient combinations
• rational selection of the most promising solubility enhancement technologies
• prevention of time-consuming formulation and process development rework
• scalable modeling platform for late-stage product development

Presented by

Matthew D. Wessel, PhD,

Principal Scientist, Pharma Services, Patheon, part of Thermo Fisher Scientific

Matt Wessel has more than 20 years of experience in the pharmaceutical industry as a computational chemist. Matt is currently a Principal Scientist at Patheon based in our Early Development Center of Excellence in Bend, Oregon. In his current role, he is primarily responsible for developing predictive computational approaches that address challenging solubility and formulation problems.

Prior to Patheon, Matt spent ten formative years at Pfizer working as a modeler on several drug discovery projects. Along the way, Matt earned invaluable experience in medicinal chemistry, formulation science and information technology. Prior to joining Pfizer, Matt worked for Bend Research and was a Solutions Architect at Schrodinger. This combination of skills and experience allows Matt to impact a multitude of areas within Patheon and uniquely places him at the forefront of our predictive modeling efforts. Matt holds a BS in Chemistry from Washington State University and earned his PhD in Chemistry from The Pennsylvania State University.

Vance Cooper,

Director, Pharmaceutics & Process Technology Pharma Services, Patheon, part of Thermo Fisher Scientific


Vance Cooper has nearly 20 years of experience in the contract pharmaceutical industry. He currently serves as head of Pharmaceutics and Process Technology with Patheon. In his role, he oversees the teams responsible for both the development and manufacture of formulations supporting early phase clinical programs. During his tenure, he has helped numerous pharmaceutical companies advance more than 25 compounds to clinic.

Vance held dual roles as Project Manager and QC Supervisor at Agere Pharmaceuticals in 2012, it was later acquired by Patheon in 2015. As the company grew, he moved into a Project Management leadership position. Prior to Patheon, Vance developed, validated and managed bioanalytical projects at PPD; managed the QC lab at AVI Biopharma, a small biopharmaceutical company; and worked as a Sr. Project Manager at BASi managing bioanalytical projects. Vance has a BS in biology from the College of William and Mary in Williamsburg, Virginia.

Ian McIntosh,

Business Manager, Pharma Services, Patheon, part of Thermo Fisher Scientific


Ian McIntosh currently serves as a Business Manager at Patheon. Based in one of our Early Development Centers of Excellence in Bend, Oregon, Ian is primarily responsible for developing predictive in vitro and in silico tools to optimize and expedite formulation development for enabling technologies. Ian has been with Patheon since 2013.

Prior to his current role, he was a Technical Project Leader with Patheon. Ian has an Master's Degree in chemistry, with an organic synthesis focus, from the University of Oregon.

Key Learning Objectives

  • Learn the benefits of addressing solubility earlier in development
  • Discover how computer and molecular modeling techniques can help determine which technologies are most likely to address low solubility
  • Find out how computational methods can inform you on the best drug-excipient combinations to develop
  • Learn how to accelerate your molecule through clinical development by preventing rework and inefficiencies from trial-and-error approaches

Audience

  • Heads of R&D
  • Heads of CMC
  • Scientists
  • Principal Scientists
  • Heads of Preclinical
  • Heads of Formulation
  • Director Process Development
  • Director Product Development
  • Director Pharmaceutics